Robyn Karnauskas
Stock Analyst at Truist Securities
(2.44)
# 2,468
Out of 5,154 analysts
177
Total ratings
43.42%
Success rate
0.13%
Average return
Main Sectors:
Stocks Rated by Robyn Karnauskas
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Buy | $1,038 → $1,182 | $990.33 | +19.35% | 6 | Nov 19, 2025 | |
| ABCL AbCellera Biologics | Maintains: Buy | $28 → $10 | $3.45 | +189.86% | 2 | May 16, 2025 | |
| AMGN Amgen | Maintains: Hold | $333 → $298 | $369.53 | -19.36% | 12 | Jan 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $65 | $60.29 | +7.81% | 2 | Jan 8, 2025 | |
| MRK Merck & Co. | Downgrades: Hold | $130 → $110 | $115.79 | -5.00% | 11 | Jan 8, 2025 | |
| GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $143.93 | -42.33% | 18 | Aug 15, 2024 | |
| ABBV AbbVie | Reiterates: Buy | $195 → $210 | $230.11 | -8.74% | 8 | Jul 26, 2024 | |
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $1.39 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $184.87 | +83.91% | 17 | May 16, 2024 | |
| CRIS Curis | Maintains: Buy | $26 | $0.99 | +2,526.26% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $1.82 | +284.62% | 13 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,135 | $759.86 | +49.37% | 16 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $1.89 | +429.10% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $2.38 | +278.15% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $28.78 | -20.08% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $26.66 | +80.05% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $22.11 | +126.14% | 8 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $456.69 | +11.24% | 13 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $27.05 | +33.09% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $62.82 | -60.20% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.48 | - | 6 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $61.12 | +129.06% | 5 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30,000 | $2.16 | +1,388,788.89% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $1.33 | +426.32% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $14.27 | +285.42% | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $8.87 | +3,507.67% | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $24.86 | -39.66% | 5 | Aug 9, 2022 |
Eli Lilly and Company
Nov 19, 2025
Maintains: Buy
Price Target: $1,038 → $1,182
Current: $990.33
Upside: +19.35%
AbCellera Biologics
May 16, 2025
Maintains: Buy
Price Target: $28 → $10
Current: $3.45
Upside: +189.86%
Amgen
Jan 8, 2025
Maintains: Hold
Price Target: $333 → $298
Current: $369.53
Upside: -19.36%
Bristol-Myers Squibb Company
Jan 8, 2025
Maintains: Buy
Price Target: $62 → $65
Current: $60.29
Upside: +7.81%
Merck & Co.
Jan 8, 2025
Downgrades: Hold
Price Target: $130 → $110
Current: $115.79
Upside: -5.00%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $143.93
Upside: -42.33%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $230.11
Upside: -8.74%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.39
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $184.87
Upside: +83.91%
Curis
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $0.99
Upside: +2,526.26%
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $1.82
Upside: +284.62%
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $759.86
Upside: +49.37%
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $1.89
Upside: +429.10%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $2.38
Upside: +278.15%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $28.78
Upside: -20.08%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $26.66
Upside: +80.05%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $22.11
Upside: +126.14%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $456.69
Upside: +11.24%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $27.05
Upside: +33.09%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $62.82
Upside: -60.20%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.48
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $61.12
Upside: +129.06%
Sep 6, 2023
Reiterates: Buy
Price Target: $30,000
Current: $2.16
Upside: +1,388,788.89%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $1.33
Upside: +426.32%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $14.27
Upside: +285.42%
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $8.87
Upside: +3,507.67%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $24.86
Upside: -39.66%